Healthcare / Medical DevicesNasdaqCM
$2.03
+0.36 (+21.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 13%
FCF escenarios
weak_data · normalized FCF $-6.2M · quality 34.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
8/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-4272.2%
↓Gross Margin
56.8%
↑Debt/Equity
14.55
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-32.9%
FCF CAGR
—
FCF margin
-171107.6%
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4350.0 · net income $-8.8M · FCF $-7.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4350.00 | $4350.00 | $18600.00 | $5150.00 | $14373.00 |
| Net Income | $-8.8M | $-8.8M | $-6.6M | $-6.4M | $-4.8M |
| EBITDA | $-8.1M | $-8.1M | $-6.2M | $-6.0M | $-4.4M |
| EPS | -9.34 | -9.34 | -18.74 | -80.00 | -59.52 |
| Gross Margin | 56.8% | 56.8% | 67.3% | 45.7% | 45.1% |
| Operating Margin | -192013.1% | -192013.1% | -33902.0% | -118698.3% | -32765.6% |
| Net Margin | -201499.5% | -201499.5% | -35511.9% | -123384.3% | -33592.6% |
| Balance Sheet | |||||
| Debt/Equity | 14.55 | 14.55 | 0.14 | 6.79 | -1.02 |
| Current Ratio | 1.19 | 1.19 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.4M | $-7.4M | $-6.2M | $-5.8M | $-3.6M |
| Returns | |||||
| ROE | -4272.2% | -4272.2% | -90.3% | -2756.1% | 79.7% |
| Valuation | |||||
| P/B | 9.28 | 9.28 | 0.43 | 30.35 | — |
| Growth & Yield | |||||
| Revenue Growth | -76.6% | -76.6% | 261.2% | -64.2% | — |
| EPS Growth | 50.2% | 50.2% | 76.6% | -34.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-42.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-18.74 → -9.34
Residual
-42.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.